198 related articles for article (PubMed ID: 11552903)
21. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.
Levine A; Kori M; Dinari G; Broide E; Shaoul R; Yerushalmi B; On A; Bujanover Y; Pröls M; Greinwald R;
Inflamm Bowel Dis; 2009 Jul; 15(7):1055-61. PubMed ID: 19229988
[TBL] [Abstract][Full Text] [Related]
22. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
23. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.
D'Haens G; Verstraete A; Cheyns K; Aerden I; Bouillon R; Rutgeerts P
Aliment Pharmacol Ther; 1998 May; 12(5):419-24. PubMed ID: 9663720
[TBL] [Abstract][Full Text] [Related]
24. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
25. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
26. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
27. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM; McTavish D
Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
[TBL] [Abstract][Full Text] [Related]
28. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization.
Herfarth H; Gross V; Andus T; Caesar I; Vogelsang H; Adler G; Malchow H; Petri A; Gierend M; Schölmerich J;
Int J Colorectal Dis; 2004 Mar; 19(2):147-52. PubMed ID: 13680283
[TBL] [Abstract][Full Text] [Related]
30. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
31. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
32. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
33. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
[TBL] [Abstract][Full Text] [Related]
34. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Irvine EJ; Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Nilsson LG; Persson T
Inflamm Bowel Dis; 2000 Aug; 6(3):181-7. PubMed ID: 10961590
[TBL] [Abstract][Full Text] [Related]
35. Oral budesonide in active Crohn's disease.
Löfberg R; Danielsson A; Salde L
Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
[TBL] [Abstract][Full Text] [Related]
36. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.
Edsbäcker S; Bengtsson B; Larsson P; Lundin P; Nilsson A; Ulmius J; Wollmer P
Aliment Pharmacol Ther; 2003 Feb; 17(4):525-36. PubMed ID: 12622761
[TBL] [Abstract][Full Text] [Related]
37. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
Rutgeerts P
Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
[TBL] [Abstract][Full Text] [Related]
38. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
[TBL] [Abstract][Full Text] [Related]
40. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.
Bar-Meir S; Chowers Y; Lavy A; Abramovitch D; Sternberg A; Leichtmann G; Reshef R; Odes S; Moshkovitz M; Bruck R; Eliakim R; Maoz E; Mittmann U
Gastroenterology; 1998 Oct; 115(4):835-40. PubMed ID: 9753485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
